Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Oxycodone
Accession Number
DB00497  (APRD00387)
Type
Small Molecule
Groups
Approved, Illicit, Investigational
Description

Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.3 It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.Label The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.5

Structure
Thumb
Synonyms
  • (-)-14-Hydroxydihydrocodeinone
  • 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • Dihydro-14-hydroxycodeinone
  • Dihydrohydroxycodeinone
  • Dihydroxycodeinone
  • Oxicodona
  • Oxycodone
  • Oxycodonum
External IDs
IDS-NO-002 / N02AA05 / NSC-19043 / PF-00345439 / PTI-821
Product Ingredients
IngredientUNIICASInChI Key
Oxycodone hydrochlorideC1ENJ2TE6C124-90-3MUZQPDBAOYKNLO-RKXJKUSZSA-N
Oxycodone terephthalateM04XWV43UF124133-68-2BTEYIHUKHHAVAN-KDKWOIFOSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Oxycodone CRTablet, extended releaseOralTEVA Canada Limited2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended releaseOralTEVA Canada Limited2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended releaseOralTEVA Canada Limited2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended releaseOralTEVA Canada Limited2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended releaseOralTEVA Canada Limited2012-11-26Not applicableCanada
OxaydoTablet7.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-09-012018-12-31Us
OxaydoTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-09-012017-12-31Us
OxaydoTablet7.5 mg/1OralZyla Life Sciences US Inc.2015-09-01Not applicableUs
OxaydoTablet5 mg/1OralZyla Life Sciences US Inc.2015-09-01Not applicableUs
OxectaTablet7.5 mg/1OralPfizer Laboratories Div Pfizer Inc.2011-06-17Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxycodone CRTablet, extended releaseOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended releaseOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended releaseOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended releaseOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended releaseOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended releaseOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended releaseOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended releaseOralApotex Corporation2012-11-27Not applicableCanada
OxycodoneSolution5 mg/5mLOralAscend Laboratories, LLC2019-02-09Not applicableUs
OxycodoneSolution100 mg/5mLOralAscend Laboratories, LLC2019-02-06Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-oxycodone/acetOxycodone hydrochloride (5 mg) + Acetaminophen (325 mg)TabletOralApotex Corporation2009-04-15Not applicableCanada
CombunoxOxycodone hydrochloride (5 mg/1) + Ibuprofen (400 mg/1)TabletOralFOREST PHARMACEUTICALS, INC.2004-11-262011-03-03Us
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (650 mg/1)TabletOralEndo Pharmaceuticals Inc. DBA Endo Generic Products2000-12-012009-08-19Us
EndocetOxycodone hydrochloride (2.5 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralBlenheim Pharmacal, Inc.2008-05-282011-11-30Us
EndocetOxycodone hydrochloride (5 mg) + Acetaminophen (325 mg)TabletOralBristol Myers Squibb1995-12-312017-10-13Canada
EndocetOxycodone hydrochloride (7.5 mg/1) + Acetaminophen (500 mg/1)TabletOralEndo Pharmaceuticals Inc. DBA Endo Generic Products2000-12-062009-08-19Us
EndocetOxycodone hydrochloride (7.5 mg/1) + Acetaminophen (500 mg/1)TabletOralBlenheim Pharmacal, Inc.2008-10-082011-10-31Us
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralStat Rx USA2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralLake Erie Medical Dba Quality Care Produts Llc2003-03-062016-06-01Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Oxycodone HydrochlorideOxycodone hydrochloride (20 mg/1mL)Solution, concentrateOral8282696752013-09-232013-09-23Us
Oxycodone HydrochlorideOxycodone hydrochloride (20 mg/1mL)Solution, concentrateOralMallinckrodt2009-06-022011-10-31Us
Oxycodone HydrochlorideOxycodone hydrochloride (5 mg/1)CapsuleOralPhysicians Total Care, Inc.2006-05-082013-01-11Us
Oxycodone HydrochlorideOxycodone hydrochloride (5 mg/5mL)SolutionOralMallinckrodt2009-06-022011-10-31Us
Oxycodone HydrochlorideOxycodone hydrochloride (20 mg/1mL)Solution, concentrateOralMallinckrodt2009-06-022011-10-31Us
Oxycodone HydrochlorideOxycodone hydrochloride (20 mg/1mL)Solution, concentrateOralPhysicians Total Care, Inc.2006-01-012011-07-31Us
Oxycodone Hydrochloride Immediate-releaseOxycodone hydrochloride (5 mg/1)CapsuleOralMallinckrodt2009-06-182012-07-31Us
RoxicodoneOxycodone hydrochloride (20 mg/1mL)ConcentrateOralXanodyne Pharmaceuticals2009-05-152010-12-16Us
RoxicodoneOxycodone hydrochloride (5 mg/5mL)SolutionOralXanodyne Pharmaceuticals2009-05-152010-12-16Us
International/Other Brands
Oxanest / OxyIR
Categories
UNII
CD35PMG570
CAS number
76-42-6
Weight
Average: 315.3636
Monoisotopic: 315.147058165
Chemical Formula
C18H21NO4
InChI Key
BRUQQQPBMZOVGD-XFKAJCMBSA-N
InChI
InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O

Pharmacology

Indication

Oxycodone is indicated for the treatment of moderate to severe pain.Label There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.Label

Associated Conditions
Pharmacodynamics

Oxycodone acts directly on a number of tissues not related to its analgesic effect. These tissues include the respiratory centre in the brain stem, the cough centre in the medulla, muscles of the pupils, gastrointestinal tract, cardiovascular system, endocrine system, and immune system.Label Oxycodone's effect on the respiratory centre is dose dependant respiratory depression.Label The action on the cough centre is suppression of the cough reflex.Label Pupils become miopic or decrease in size, peristalsis of the gastrointestinal tract slows, and muscle tone in the colon may increase causing constipation.Label In the cardiovascular system histamine may be released leading to pruritis, red eyes, flushing, sweating, and decreased blood pressure.Label Endocrine effects may include increased prolactin, decreased cortisol, and decreased testosterone.Label It is not yet known if the effects of opioids on the immune system are clinically significant.Label

Mechanism of action

The full mechanism of oxycodone is not known.Label Under conditions of inflammation or hyperalgesia, opioid receptors in the heart, lungs, liver, gastrointestinal tract, and reproductive system are upregulated and transported to nerve terminals.3 Oxycodone and its active metabolites, noroxycodone, oxymorphone, and noroxymorphone are opioid agonists.1 These compounds passively diffuse across the blood brain barrier or may be actively transported across by an unknown mechanism.3 Oxycodone and its active metabolites can selectively bind to the mu opioid receptor, but also the kappa and delta opioid receptors in the central nervous system and periphery, and induce a G protein coupled receptor signalling pathway.3 Activation of mu opioid receptors inhibits N-type voltage operated calcium channels, inhibiting responses to pain.4

TargetActionsOrganism
AMu-type opioid receptor
agonist
Humans
AKappa-type opioid receptor
agonist
Humans
ADelta-type opioid receptor
agonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Oxycodone has an oral bioavailability of 60% to 87% that is unaffected by food.Label

The area under the curve is 135ng/mL*hr, maximum plasma concentration is 11.5ng/mL, and time to maximum concentration is 5.11hr in patients given a 10mg oral immediate release dose of oxycodone.Label

Volume of distribution

2.6L/kg.Label

Protein binding

45%.Label Oxycodone is primarily bound to serum albumin and to a lesser degree alpha1-acid glycoprotein.2

Metabolism

Oxycodone's metabolism is hepatic and completed by 4 main reactions. CYP3A4 and 3A5 perform N-demethylation, CYP2D6 performs O-demethylation, unknown enzymes perform 6-keto-reduction, and unknown enzymes perform conjugation.1

Oxycodone is metabolized by CYP3A4 and CYP3A5 to noroxycodone and then by CYP2D6 to noroxymorphone.1 Noroxycodone and noroxymorphone are the primary circulating metabolites.Label Noroxycodone can also be 6-keto-reduced to alpha or beta noroxycodol.1

Oxycodone can be metabolized by CYP2D6 to oxymorphone and then by CYP3A4 to noroxymorphone.1 Oxymorphone can also be 6-keto-reduced to alpha or beta oxymorphol.1

Oxycodone can also be 6-keto-reduced to alpha and beta oxycodol.1

The active metabolites noroxycodone, oxymorphone, and noroxymorphone can all be conjugated before elimination.1

Route of elimination

Oxycodone is mainly eliminated in the urine.Label Unbound noroxycodone makes up 23% of the dose recovered in urine and oxymorphone makes up <1%.Label conjugated oxymorphone makes up 10% of the recovered dose.Label Free and conjugated oxycodone makes up 8.9% of the recovered dose, noroxymorphone makes up 14%, and reduced metabolites make up 18%.Label

Half life

The apparent elimination half life of oxycodone is 3.2 hours for immediate release formulations and 4.5 hours for extended release formulations.Label Noroxycodone has a half life of 5.8 hours, oxymorphone has a half life of 8.8 hours, noroxymorphone has a half life of 9 hours.1

Clearance

Total plasma clearance is 1.4L/min in adults.Label

Toxicity

Patients experiencing an overdose may present with respiratory depression, sleepiness, stupor, coma, skeletal muscle flaccidity, cold sweat, constricted pupils, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death.Label Overdose should be treated by maintaining airway, ventilation, and oxygenation.Label Oxygen and vasopressor treatment may be necessary to treat circulatory shock and pulmonary edema and defibrillation may be required for cardiac arrest of arrhythmia.Label Naloxone, nalmefene, or naltrexone may be used to counteract the effects of opioids but patients should be monitored in case further doses are required.Label

The intraperitoneal LD50 in mice is 320mg/kg, the oral LD50 is 426mg/kg.MSDS The oral lowest dose causing toxic effects in humans is 0.14mg/kg and subcutaneously in rats it is 1.53mg/kg.MSDS

Oxycodone is pregnancy category B according to the FDA.Label There is a paucity of data regarding oxycodone use in pregnancy, though animal studies show no teratogenic effects.Label Rats given oxycodone during lactation showed smaller offspring, though after lactation, they recovered to normal size.Label Oxycodone is excreted in breast milk and so patients should not breastfeed while taking oxycodone due to risk of sedation and respiratory depression in infants.Label

No studies on the carcinogenicity of oxycodone have been performed.Label Oxycodone was genotoxic at 50mcg/mL with metabolic activation and at 400mcg/mL without.Label It was also clastogenic with metabolic activation at ≥1250mcg/mL.Label Oxycodone was not found to be genotoxic in other tests.Label Oxycodone does not affect reproduction and fertility in rats at doses of up to 8mg/kg/day.Label

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Oxycodone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidineThe metabolism of Oxycodone can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Oxycodone.
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Oxycodone.
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxycodone.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.
AbataceptThe metabolism of Oxycodone can be increased when combined with Abatacept.
AbirateroneThe metabolism of Oxycodone can be decreased when combined with Abiraterone.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, "Preparation of oxycodone from codeine." U.S. Patent US6008355, issued March, 1990.

US6008355
General References
  1. DePriest AZ, Puet BL, Holt AC, Roberts A, Cone EJ: Metabolism and Disposition of Prescription Opioids: A Review. Forensic Sci Rev. 2015 Jul;27(2):115-45. [PubMed:26227254]
  2. Leow KP, Wright AW, Cramond T, Smith MT: Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit. 1993 Oct;15(5):440-7. [PubMed:8249052]
  3. Ruan X, Mancuso KF, Kaye AD: Revisiting Oxycodone Analgesia: A Review and Hypothesis. Anesthesiol Clin. 2017 Jun;35(2):e163-e174. doi: 10.1016/j.anclin.2017.01.022. Epub 2017 Mar 14. [PubMed:28526158]
  4. Andrade A, Denome S, Jiang YQ, Marangoudakis S, Lipscombe D: Opioid inhibition of N-type Ca2+ channels and spinal analgesia couple to alternative splicing. Nat Neurosci. 2010 Oct;13(10):1249-56. doi: 10.1038/nn.2643. Epub 2010 Sep 19. [PubMed:20852623]
  5. FDA Approved Drug Products: Percodan [Link]
External Links
Human Metabolome Database
HMDB0014640
KEGG Drug
D05312
KEGG Compound
C08018
PubChem Compound
5284603
PubChem Substance
46508908
ChemSpider
4447649
BindingDB
50370595
ChEBI
7852
ChEMBL
CHEMBL656
Therapeutic Targets Database
DAP000283
PharmGKB
PA450741
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxycodone
ATC Codes
N02AA56 — Oxycodone and naltrexoneN02AA05 — OxycodoneN02AA55 — Oxycodone and naloxoneN02AJ18 — Oxycodone and acetylsalicylic acidN02AJ17 — Oxycodone and paracetamolN02AJ19 — Oxycodone and ibuprofen
AHFS Codes
  • 28:08.08 — Opiate Agonists
FDA label
Download (238 KB)
MSDS
Download (23.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentLocally Advanced Head and Neck Cancer1
0RecruitingBasic ScienceOpioid Use Disorders1
0RecruitingBasic SciencePrescription Drug Abuse (Not Dependent)1
0RecruitingPreventionOpioid Abuse, Unspecified / Opioid Dependence1
0RecruitingSupportive CareMetastatic Malignant Neoplasm / Neoplasms, Malignant / Pain1
0RecruitingTreatmentTotal Knee Arthroplasty (TKA)1
0RecruitingTreatmentUrologic Diseases1
1CompletedNot AvailableHealthy Volunteers17
1CompletedNot AvailableOpioid Analgesia1
1CompletedNot AvailablePain1
1CompletedBasic ScienceAnalgesia / Narcotic Abuse / Opioid-Related Disorders / Pain, Acute / Pain, Chronic1
1CompletedBasic ScienceHealthy Volunteers11
1CompletedBasic ScienceManagement of Moderate to Severe Pain1
1CompletedBasic ScienceOpioid Users1
1CompletedBasic SciencePain2
1CompletedBasic ScienceRespiratory Depression1
1CompletedBasic ScienceSubstance Abuse1
1CompletedOtherHealthy Volunteers2
1CompletedOtherOpioid Abuse Nondependent1
1CompletedOtherOsteoarthritis Thumbs1
1CompletedOtherPain, Chronic4
1CompletedSupportive CareHead and Neck Squamous Cell Carcinoma (HNSCC) / Pain / Stomatitis1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentPain2
1Not Yet RecruitingTreatmentIntervertebral Disc Degeneration / Spondylolisthesis, Lumbar Region1
1RecruitingBasic ScienceBack Pain Lower Back Chronic / Moderate to Severe Chronic Pain1
1RecruitingBasic SciencePain / Substance Abuse1
1RecruitingOtherImpacted Third Molar Tooth / Pain, Acute1
1RecruitingTreatmentAnalgesia1
1RecruitingTreatmentBack Pain Lower Back1
1RecruitingTreatmentColorectal Cancers1
1, 2CompletedTreatmentPain, Fracture, Sprain1
1, 2RecruitingTreatmentAdenotonsillectomy / Analgesia, Postoperative / Opioids Use1
2CompletedBasic ScienceModerate to Severe Pain Due to Diabetic Polyneuropathy1
2CompletedBasic ScienceOpioid-Related Disorders / Substance-Related Disorders1
2CompletedSupportive CareAdvanced Solid Cancers1
2CompletedSupportive CareCarpal Tunnel Syndrome (CTS) / Cystic tumour of the ganglia / De Quervain's Disease / Dupuytren's Contracture of the Hand (Viking's Disease) / Trigger Digit1
2CompletedSupportive CareNutrition Disorders / Quality of Life1
2CompletedSupportive CarePain1
2CompletedTreatmentConstipation / Malignancies / Pain1
2CompletedTreatmentDental Pain1
2CompletedTreatmentGeneral Surgery1
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentInterstitial Cystitis / Pain / Painful Bladder Syndrome (PBS)1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)2
2CompletedTreatmentMalignancies / Pain1
2CompletedTreatmentModerate to Severe Chronic Pain Due to Osteoarthritis of the Knee1
2CompletedTreatmentOpioid Abuse1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentOrthopaedic Related Pain (Musculoskeletal Pain)1
2CompletedTreatmentPain, Acute1
2CompletedTreatmentPostoperative pain3
2CompletedTreatmentTonsillectomy1
2RecruitingPreventionPain, Neuropathic1
2RecruitingTreatmentFusion of Spine (Disease) / Opioid-Related Disorders / Opioids Use / Rib Fractures / Traumas1
2RecruitingTreatmentHernia, Abdominal / Pain1
2RecruitingTreatmentOpioid-use Disorder1
2RecruitingTreatmentPain Management1
2RecruitingTreatmentPreeclampsia Postpartum / Severe Preeclampsia1
2RecruitingTreatmentSpinal Cord Injuries (SCI)1
2TerminatedTreatmentJoint Pain / Knee Osteoarthritis (Knee OA) / Osteoarthritis (OA) / Pain1
2TerminatedTreatmentOsteoarthritis (OA)1
2TerminatedTreatmentToothache1
2, 3CompletedTreatmentMalignant Pain / Non-malignant Pain1
2, 3RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
2, 3RecruitingTreatmentParkinson's Disease (PD)1
3Active Not RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3Active Not RecruitingTreatmentBrachial Plexus Block / Postoperative pain1
3Active Not RecruitingTreatmentGynecologic Cancers / Malignant Neoplasms of Female Genital Organs1
3CompletedNot AvailableSubjects With Moderate to Severe, Chronic Nonmalignant Pain1
3CompletedNot AvailableWithdrawal Symptoms1
3CompletedBasic ScienceBack Pain Lower Back1
3CompletedSupportive CareAnalgesia After ED Discharge for Extremity Injuries1
3CompletedSupportive CareChronic Noncancer Pain1
3CompletedSupportive CarePain1
3CompletedTreatmentAbortion in First Trimester1
3CompletedTreatmentAnalgesia / Back Pain Lower Back / Pain, Chronic1
3CompletedTreatmentArthritis / Joint Diseases / Osteoarthritis (OA)1
3CompletedTreatmentBack Pain Lower Back4
3CompletedTreatmentBack Pain Lower Back Chronic1
3CompletedTreatmentBack Pain Lower Back / Back Pain With Radiation / Back Pain, Unspecified / Pain1
3CompletedTreatmentBack Pain Lower Back / Knee Osteoarthritis (Knee OA) / Osteoarthritis, Hip / Pain1
3CompletedTreatmentBack Pain, Unspecified1
3CompletedTreatmentBunions / Hallux Valgus / Joint Pain / Pain1
3CompletedTreatmentChronic Osteoarthritis1
3CompletedTreatmentConstipation / Pain1
3CompletedTreatmentKidney Stones1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Pain2
3CompletedTreatmentLiver Cancer / Postoperative pain1
3CompletedTreatmentMalignancies1
3CompletedTreatmentMalignancies / Pain1
3CompletedTreatmentModerate to Severe Idiopathic RLS With Daytime Symptoms1
3CompletedTreatmentModerate to Severe Postoperative Pain1
3CompletedTreatmentModerate-to-severe Chronic Low Back Pain1
3CompletedTreatmentModerate-to-severe Chronic Noncancer Pain1
3CompletedTreatmentNon Cancer Pain1
3CompletedTreatmentOpioids Use / Pain, Chronic1
3CompletedTreatmentOther Acute Postoperative Pain1
3CompletedTreatmentPain13
3CompletedTreatmentPain, Chronic2
3CompletedTreatmentParkinson's Disease With Severe Pain1
3CompletedTreatmentPost Operative Nausea and Vomiting (PONV) / Postoperative pain1
3CompletedTreatmentPostoperative pain5
3CompletedTreatmentPruritus1
3RecruitingSupportive CareBreast - Female1
3RecruitingSupportive CareCalcium Nephrolithiasis1
3RecruitingTreatmentBack Pain, Unspecified / Neck Pain1
3RecruitingTreatmentBone Metastases / Malignant Lymphomas / Multiple Myeloma (MM) / Opioids Use / Pain1
3RecruitingTreatmentJoint Diseases1
3RecruitingTreatmentOpioids Use / Shoulder Pain1
3TerminatedTreatmentArthroplasty1
3TerminatedTreatmentBack Pain Lower Back Chronic1
3TerminatedTreatmentConstipation / Pain1
3TerminatedTreatmentDiabetic Neuropathy, Painful / Diabetic Polyneuropathy1
3TerminatedTreatmentOsteoarthritis (OA)2
3TerminatedTreatmentSevere Caner Pain1
3Unknown StatusSupportive CareMalignancies / Pain1
3Unknown StatusTreatmentCancer Related Pain (Breakthrough Pain)1
3WithdrawnTreatmentPain1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedNot AvailablePain1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceHealthy, no Evidence of Disease1
4CompletedBasic ScienceSubstance-Related Disorders1
4CompletedDiagnosticPain1
4CompletedSupportive CareEffects of 2 Mu-opiates on Gastrointestinal Transit1
4CompletedSupportive CareMalignancies1
4CompletedSupportive CarePain, Cancer1
4CompletedSupportive CarePain, Chronic1
4CompletedSupportive CarePain / Unspecified Adult Solid Tumor, Protocol Specific1
4CompletedSupportive CareSpinal Disorders / Spinal Disorders Related Pain1
4CompletedTreatmentAbortion Second Trimester1
4CompletedTreatmentAcute Low Back Pain1
4CompletedTreatmentAnalgesics, Antipyretics, and Antirheumatics Causing Adverse Effects in Therapeutic Use / Opioids Use / Pain Uterus / Pain, Acute / Postoperative pain / Visceral Pain1
4CompletedTreatmentAnterior Cruciate Ligament Reconstruction1
4CompletedTreatmentAnxiety / Back Pain Lower Back Chronic / Depression / Intervertebral Disc Degeneration1
4CompletedTreatmentArthroplasty, Replacement, Hip1
4CompletedTreatmentBack Pain Lower Back / Back Pain, Unspecified / Pain, Neuropathic1
4CompletedTreatmentBack Pain, Unspecified / Osteoarthritis (OA)1
4CompletedTreatmentBenign muscle neoplasm / Hysterectomy / Opioids / Postoperative pain1
4CompletedTreatmentBlood Pressures / Intubation Complications1
4CompletedTreatmentConstipation1
4CompletedTreatmentConstipation / Narcotic Use / Nausea / Pain1
4CompletedTreatmentCritical Illness1
4CompletedTreatmentDiseases of Mitral Valve / Postoperative pain1
4CompletedTreatmentDisorder of Knee1
4CompletedTreatmentEpidural Analgesia / Oral Oxycodone With/Without Naloxone / Postoperative Pain Management / Radical Cystectomy / Return of the Bowel Function1
4CompletedTreatmentFlank Pain / Urinary Bladder, Overactive1
4CompletedTreatmentFracture Bone1
4CompletedTreatmentGeneral Surgery1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart; Dysfunction Postoperative, Cardiac Surgery1
4CompletedTreatmentMAB / Pain1
4CompletedTreatmentMalignancies2
4CompletedTreatmentMalignancies / Pain, Cancer1
4CompletedTreatmentImpaired kidney function / Myocardial Infarction / Postoperative pain1
4CompletedTreatmentNausea1
4CompletedTreatmentOocyte Retrieval / Postoperative pain1
4CompletedTreatmentOpioid Related Disorders / Postoperative pain1
4CompletedTreatmentOral Sedation and Cervical Dilator Pain1
4CompletedTreatmentOsteoarthritis (OA) / Pain, Chronic1
4CompletedTreatmentPain2
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPelvic Organ Prolapse (POP) / Postoperative pain1
4CompletedTreatmentPost Operative Pain2
4CompletedTreatmentPostcraniotomy Pain1
4CompletedTreatmentPostoperative pain3
4CompletedTreatmentUnilateral Knee Arthroplasty1
4Enrolling by InvitationTreatmentAnalgesia, Patient-Controlled1
4Not Yet RecruitingTreatmentAchalasia1
4Not Yet RecruitingTreatmentCancer Pains1
4Not Yet RecruitingTreatmentOrthopaedic Related Pain (Musculoskeletal Pain)1
4Not Yet RecruitingTreatmentPain2
4Not Yet RecruitingTreatmentPostoperative pain1
4RecruitingBasic ScienceChronic Kidney Disease (CKD)1
4RecruitingOtherOpioid Substitution Treatment1
4RecruitingOtherPediatric Surgical Patient1
4RecruitingSupportive CareBack Pain Lower Back1
4RecruitingSupportive CareDeglutition / Opioids Use / Pain, Chronic1
4RecruitingSupportive CareScoliosis / Spondylolisthesis1
4RecruitingTreatmentConstipation / Postoperative pain1
4RecruitingTreatmentDiseases of Mitral Valve / Postoperative pain1
4RecruitingTreatmentDistal Radius Fractures / Metacarpal Fractures / Pain Management1
4RecruitingTreatmentHip Arthroscopy1
4RecruitingTreatmentInguinal Hernias / Postoperative pain1
4RecruitingTreatmentKidney Stones / Ureteral Calculus1
4RecruitingTreatmentLabour Pain1
4RecruitingTreatmentLiquid Oxycodone1
4RecruitingTreatmentNarcotic Use / Opioid Abuse / Opioids Use / Otolaryngologic Disease / Pain / Postoperative pain / Sinusitis1
4RecruitingTreatmentOpioids Use1
4RecruitingTreatmentOxycodone / Pharmacogenomics / Pharmacokinetics1
4RecruitingTreatmentPain2
4RecruitingTreatmentPain Management1
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPain, Chronic2
4RecruitingTreatmentPost Operative Nausea and Vomiting (PONV) / Postoperative Hemorrhages / Postoperative pain / Weight Changes1
4RecruitingTreatmentPost Operative Pain / Sinus Surgery1
4RecruitingTreatmentPostoperative pain3
4RecruitingTreatmentPostoperative pain / Urethral Strictures1
4RecruitingTreatmentSleep Apnea1
4RecruitingTreatmentSupracondylar Humerus Fractures1
4RecruitingTreatmentTendon Injuries1
4SuspendedTreatmentPain1
4SuspendedTreatmentPain, Chronic1
4TerminatedNot AvailablePeripheral neuropathy1
4TerminatedSupportive CareImpaired kidney function / Pain / Terminal Illness1
4TerminatedTreatmentAnesthesia Recovery Period / Postoperative pain1
4TerminatedTreatmentArthritis / Cognitive Impairments / Pain1
4TerminatedTreatmentDisseminated Sclerosis / Pain, Chronic / Pain, Neuropathic1
4TerminatedTreatmentModerate-severe Pain / Moderate-severe Pain (All Types)1
4TerminatedTreatmentNarcotic Abuse / Opiate Addiction / Opioid-Related Disorders / Substance Abuse1
4TerminatedTreatmentPain, Chronic1
4TerminatedTreatmentPostoperative pain1
4Unknown StatusNot AvailableOpioid Induced Constipation (OIC) / Postoperative pain1
4Unknown StatusTreatmentBack Pain Lower Back1
4Unknown StatusTreatmentElective Laproscopic Bilateral Inguinal Hernia / Elective Laproscopic Cholecystectomy1
4Unknown StatusTreatmentPost Operative Pain1
4WithdrawnTreatmentKidney Stones / Postoperative pain1
4WithdrawnTreatmentPain, Chronic1
4WithdrawnTreatmentPost Operative Pain Control1
Not AvailableActive Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
Not AvailableActive Not RecruitingTreatmentAnaesthesia therapy / Arthropathy of Knee Joint / Knee Osteoarthritis (Knee OA) / Knee Pain Chronic / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailableAdverse Effects / Nausea, Postoperative / Opioid Analgesic Adverse Reaction / Pain1
Not AvailableCompletedNot AvailableCancer Related Pain (Breakthrough Pain) / Pain, Cancer / Pain, Neuropathic / Tumors1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableNeoplasms / Pain, Cancer1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailableSevere Pain1
Not AvailableCompletedNot AvailableSevere, Chronic Pain1
Not AvailableCompletedNot AvailableSubstance Abuse Detection1
Not AvailableCompletedBasic ScienceNarcotic Abuse1
Not AvailableCompletedOtherCardiovascular1
Not AvailableCompletedPreventionCoughing Responses at Tracheal Extubation1
Not AvailableCompletedPreventionPost Operative Nausea and Vomiting (PONV)1
Not AvailableCompletedTreatmentCalcium Nephrolithiasis / Ureteral Calculus1
Not AvailableCompletedTreatmentCritical Illness1
Not AvailableCompletedTreatmentDrug Drug Interaction (DDI)1
Not AvailableCompletedTreatmentElbow Fractures1
Not AvailableCompletedTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableCompletedTreatmentHip Fracture Surgery / Post Operative Pain Control1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentLabour Pain1
Not AvailableCompletedTreatmentPost Cesarean Pain Management1
Not AvailableCompletedTreatmentPost Operative Pain1
Not AvailableNot Yet RecruitingOtherOpioid Use, Unspecified1
Not AvailableNot Yet RecruitingTreatmentHerpes Zoster / Post-Herpetic Neuralgia (PHN)1
Not AvailableNot Yet RecruitingTreatmentOsteoarthritis (OA)1
Not AvailableNot Yet RecruitingTreatmentPeripheral Arterial Disease (PAD)1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiety / Anxiolysis / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Bradycardia / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Cardiac Dysrhythmia / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Chronic Kidney Disease (CKD) / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infection / Convulsions / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Endocarditis / Epilepsies / Fibrinolytic Bleeding / Flu caused by Influenza / Gastroparesis / Gram-negative Infection / Gynaecological infection / Headache / Heart Failure / Heavy Menstrual Bleeding / Hemophilia / Herpes Simplex Virus / High Blood Pressure (Hypertension) / High Cholesterol / Hospital-acquired bacterial pneumonia / Hyperaldosteronism / Hyperlipidemias / Hypokalemia / Hypotension / Infantile Hemangiomas / Infection caused by staphylococci / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Insomnia / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Methicillin Resistant Staphylococcus Aureus (MRSA) / Migraine / Muscle Spasms / Nausea / Neuromuscular Blockade / Neutropenia / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Pulmonary Arterial Hypertension (PAH) / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombotic events / Toxic effect of hydrocyanic acid and cyanides / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infection / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableMultimodal Analgesia / Nonsteroidal Anti-inflammatory Drugs1
Not AvailableRecruitingNot AvailableOxycontin1
Not AvailableRecruitingSupportive CareStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 / Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v81
Not AvailableRecruitingTreatmentBMI >30 kg/m2 / Postoperative pain1
Not AvailableRecruitingTreatmentChronic Pain, Postoperative / Postoperative pain1
Not AvailableRecruitingTreatmentGeneral Surgery / Pain / Rib Fractures / Traumas1
Not AvailableRecruitingTreatmentHip Pain Chronic1
Not AvailableRecruitingTreatmentNasopharyngeal Carcinoma1
Not AvailableRecruitingTreatmentParathyroid Diseases / Thyroid Diseases1
Not AvailableSuspendedTreatmentLaceration / Pain1
Not AvailableTerminatedNot AvailableOsteoarthritis (OA)1
Not AvailableTerminatedSupportive CareBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Pain / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedTreatmentAnaesthesia therapy1
Not AvailableTerminatedTreatmentPain, Acute1
Not AvailableTerminatedTreatmentPost-op Pain1
Not AvailableTerminatedTreatmentUndesired Pregnancy1
Not AvailableUnknown StatusNot AvailableAnalgesic Response1
Not AvailableUnknown StatusNot AvailableHip Fracture1
Not AvailableUnknown StatusTreatmentPost Tonsillectomy Pain1
Not AvailableWithdrawnSupportive CareBack Pain Lower Back1

Pharmacoeconomics

Manufacturers
  • Mallinckrodt inc
  • Purdue pharma lp
  • Roxane laboratories inc
  • Actavis totowa llc
  • Avanthi inc
  • Corepharma llc
  • Kv pharmaceutical co
  • Sun pharmaceutical industries inc
  • Tyco healthcare mallinckrodt
  • Vintage pharmaceuticals inc
  • Xanodyne pharmaceuticals inc
  • Endo Pharmaceuticals
Packagers
  • 4uOrtho LLC
  • Actavis Group
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • Athlon Pharmaceuticals Inc.
  • Atley Pharmaceuticals
  • Barr Pharmaceuticals
  • Blenheim Pharmacal
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Chattem Chemicals Inc.
  • Cody Laboratories Inc.
  • Core Pharmaceuticals
  • Corepharma LLC
  • D.M. Graham Laboratories Inc.
  • DAVA Pharmaceuticals
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dorx LLC
  • DSM Corp.
  • Endo Pharmaceuticals Inc.
  • Endogen
  • Ethex Corp.
  • Forest Pharmaceuticals
  • Glenmark Generics Ltd.
  • Global Pharmaceuticals
  • Impax Laboratories Inc.
  • Ivax Pharmaceuticals
  • Janssen-Ortho Inc.
  • KV Pharmaceutical Co.
  • KVK-Tech Inc.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Lehigh Valley Technologies Inc.
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • Metrics Inc.
  • Midlothian Labs
  • Mikart Inc.
  • Mylan
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals Inc.
  • P F Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Purdue Pharma LP
  • Qualitest
  • Quality Care
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Rhodes Pharmaceutical LP
  • Roxane Labs
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Superior Pharmeceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Ther-Rx Corp.
  • Victory Pharma
  • Vindex Pharmaceuticals Inc.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Watson Pharmaceuticals
  • WraSer Pharmaceuticals
  • Xanodyne Pharmaceuticals Inc.
Dosage forms
FormRouteStrength
Tablet, extended releaseOral
TabletOral7.5 mg/1
Tablet, multilayer, extended releaseOral
TabletOral10 mg
TabletOral20 mg
TabletOral5 mg
CapsuleOral
Capsule, gelatin coatedOral
TabletOral
Tablet, coatedOral
CapsuleOral5 mg/1
SolutionOral100 mg/5mL
SolutionOral20 mg/1mL
Solution, concentrateOral20 mg/1mL
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
TabletOral80 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral80 mg/1
Tablet, film coatedOral
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral80 mg/1
Tablet, extended releaseOral15 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral160 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral60 mg/1
SolutionOral
ConcentrateOral20 mg/1mL
SolutionOral5 mg/5mL
Tablet, coatedOral15 mg/1
Tablet, coatedOral30 mg/1
Tablet, coatedOral5 mg/1
SuppositoryRectal
TabletOral
Tablet, extended releaseOral
Capsule, extended releaseOral
Capsule, extended releaseOral13.5 mg/1
Capsule, extended releaseOral18 mg/1
Capsule, extended releaseOral27 mg/1
Capsule, extended releaseOral36 mg/1
Capsule, extended releaseOral9 mg/1
Prices
Unit descriptionCostUnit
Oxycodone hcl powder53.64USD g
Roxicodone 5 mg/5ml Solution 500ml Bottle53.0USD bottle
Roxicodone 20 mg/ml Concentrate 30ml Bottle46.99USD bottle
OxyCODONE HCl 20 mg/ml Concentrate 30ml Bottle33.99USD bottle
Oxycontin 60 mg tablet17.08USD tablet
OxyCONTIN 80 mg 12 Hour tablet14.36USD tablet
Oxycontin 20 mg tablet11.87USD tablet
Oxycontin 80 mg tablet11.53USD tablet
OxyCONTIN 60 mg 12 Hour tablet10.57USD tablet
Oxycontin 40 mg tablet9.45USD tablet
OxyCODONE HCl 80 mg 12 Hour tablet8.33USD tablet
OxyCONTIN 40 mg 12 Hour tablet7.68USD tablet
Oxycontin 10 mg tablet6.89USD tablet
Oxycontin 30 mg tablet6.59USD tablet
OxyCONTIN 30 mg 12 Hour tablet5.8USD tablet
Roxicodone 30 mg tablet5.19USD tablet
Oxycontin 80 mg Sustained-Release Tablet4.69USD tablet
OxyCODONE HCl 40 mg 12 Hour tablet4.38USD tablet
OxyCONTIN 20 mg 12 Hour tablet4.27USD tablet
Oxycontin 60 mg Sustained-Release Tablet3.55USD tablet
Oxycontin 15 mg tablet3.22USD tablet
Supeudol 20 mg Suppository2.95USD suppository
Roxicodone 15 mg tablet2.83USD tablet
Oxycodone hcl 10 mg tablet2.82USD tablet
Endocet 10-650 mg tablet2.7USD tablet
Endocet 7.5-325 mg tablet2.54USD tablet
Oxycontin 40 mg Sustained-Release Tablet2.54USD tablet
OxyCONTIN 10 mg 12 Hour tablet2.53USD tablet
Supeudol 10 mg Suppository2.33USD suppository
Roxicodone intensol 20 mg/ml2.3USD ml
Endocet 7.5-500 mg tablet2.22USD tablet
Oxycodone-apap 2.5-325 mg tablet2.05USD tablet
Percodan 4.5-0.38-325 mg tablet1.98USD tablet
Oxycontin 30 mg Sustained-Release Tablet1.96USD tablet
Endocet 10-325 mg tablet1.87USD tablet
Endocet 5-325 tablet1.82USD tablet
Percodan tablet1.62USD tablet
Oxycontin 20 mg Sustained-Release Tablet1.46USD tablet
Dazidox 20 mg tablet1.44USD tablet
Oxycodone hcl 30 mg tablet1.41USD tablet
Oxycontin 15 mg Sustained-Release Tablet1.19USD tablet
Endodan 4.83-325 mg tablet1.18USD tablet
Oxycodone hcl 20 mg tablet1.1USD tablet
Oxycontin 10 mg Sustained-Release Tablet0.98USD tablet
Oxycodone hcl 15 mg tablet0.9USD tablet
Oxycodone hcl 5 mg tablet0.81USD tablet
Dazidox 10 mg tablet0.75USD tablet
Oxy-Ir 20 mg Tablet0.74USD tablet
OxyCODONE HCl 5 mg capsule0.71USD capsule
Oxycontin 5 mg Sustained-Release Tablet0.7USD tablet
Endocet 5-325 mg tablet0.6USD tablet
Roxicodone 5 mg tablet0.56USD tablet
Oxyir 5 mg capsule0.52USD capsule
Oxy-Ir 10 mg Tablet0.43USD tablet
Pms-Oxycodone 20 mg Tablet0.42USD tablet
Supeudol 20 mg Tablet0.42USD tablet
Oxycodone 5 mg tablet0.36USD tablet
Pms-Oxycodone 10 mg Tablet0.24USD tablet
Supeudol 10 mg Tablet0.24USD tablet
Pms-Oxycodone 5 mg Tablet0.14USD tablet
Supeudol 5 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5508042No1996-04-162013-04-16Us
CA2098738No1999-08-172012-11-25Canada
US9205082No2015-12-082022-05-10Us
US6488962No2002-12-032020-06-20Us
US8309060No2012-11-132023-11-20Us
US8808741No2014-08-192027-08-24Us
US9073933No2015-07-072025-03-30Us
US9060976No2015-06-232022-08-06Us
US6488963No2002-12-032017-06-24Us
US7674800No2010-03-092025-03-30Us
US7683072No2010-03-232025-03-30Us
US8337888No2012-12-252022-08-06Us
US7776314No2010-08-172025-04-19Us
US8894988No2014-11-252027-08-24Us
US7674799No2010-03-092025-03-30Us
US8114383No2012-02-142024-10-10Us
US8894987No2014-11-252030-03-29Us
US8685443No2014-04-012025-07-03Us
US7815934No2010-10-192027-12-12Us
US9168252No2015-10-272022-05-10Us
US9161937No2015-10-202022-05-10Us
US8969369No2015-03-032022-05-10Us
US9084729No2015-07-212022-05-10Us
US9283216No2016-03-152022-05-10Us
US9056051No2015-06-162022-05-10Us
US8846090No2014-09-302023-04-04Us
US6277384No2001-08-212018-12-22Us
US8822487No2014-09-022018-12-22Us
US8673355No2014-03-182018-12-22Us
US6696066No2004-02-242018-12-22Us
US8846091No2014-09-302023-04-04Us
US8372432No2013-02-122029-03-11Us
US8668929No2014-03-112029-03-11Us
US8377453No2013-02-192029-11-19Us
US7976870No2011-07-122027-06-01Us
US8741885No2014-06-032032-05-16Us
US8992975No2015-03-312032-05-16Us
US8597681No2013-12-032030-12-21Us
US8980319No2015-03-172030-12-21Us
US8394408No2013-03-122029-03-11Us
US9050335No2015-06-092032-05-16Us
US8658631No2014-02-252032-05-16Us
US7510726No2009-03-312023-11-26Us
US8409616No2013-04-022023-11-26Us
US7201920No2007-04-102025-03-16Us
US8637540No2014-01-282023-11-26Us
US7981439No2011-07-192023-11-26Us
US7955619No2011-06-072028-08-12Us
US9492389No2016-11-152027-08-24Us
US9522919No2016-12-202025-03-30Us
US9492392No2016-11-152027-08-24Us
US9492391No2016-11-152027-08-24Us
US9492393No2016-11-152027-08-24Us
US9345701No2016-05-242022-05-10Us
US9511066No2016-12-062022-05-10Us
US9555000No2017-01-312023-04-04Us
US9474750No2016-10-252018-12-22Us
US9283221No2016-03-152022-05-10Us
US9468636No2016-10-182032-05-16Us
US9492443No2016-11-152024-05-26Us
US9044398No2015-06-022023-07-07Us
US7771707No2010-08-102025-03-24Us
US9248195No2016-02-022023-07-07Us
US8557291No2013-10-152025-03-21Us
US8449909No2013-05-282025-03-24Us
US7399488No2008-07-152025-03-24Us
US9592200No2017-03-142023-07-07Us
US9682075No2017-06-202030-12-10Us
US8758813No2014-06-242025-06-10Us
US8840928No2014-09-232023-07-07Us
US9675610No2017-06-132023-06-16Us
US9737530No2017-08-222036-09-02Us
US9763933No2017-09-192027-08-24Us
US9770416No2017-09-262027-08-24Us
US9775808No2017-10-032027-08-24Us
US9763883No2017-09-192023-07-07Us
US9907793No2018-03-062023-04-04Us
US9968598No2018-05-152036-09-02Us
US10004729No2018-06-262030-12-10Us
US10130591No2018-11-202023-11-20Us
US10188644No2019-01-292036-09-02Us
US10314788No2008-08-122028-08-12Us
US10369109No2003-06-162023-06-16Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)219http://www.chemspider.com/Chemical-Structure.4447649.html
water solubility166mg/mLhttp://www.chemspider.com/Chemical-Structure.4447649.html
logP0.7https://www.ncbi.nlm.nih.gov/pubmed/8159633
Predicted Properties
PropertyValueSource
Water Solubility5.59 mg/mLALOGPS
logP1.04ALOGPS
logP1.03ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity84.04 m3·mol-1ChemAxon
Polarizability32.8 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9885
Caco-2 permeable+0.7774
P-glycoprotein substrateSubstrate0.8996
P-glycoprotein inhibitor IInhibitor0.539
P-glycoprotein inhibitor IINon-inhibitor0.9122
Renal organic cation transporterNon-inhibitor0.5413
CYP450 2C9 substrateNon-substrate0.822
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7796
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9431
CYP450 2D6 inhibitorNon-inhibitor0.5131
CYP450 2C19 inhibitorNon-inhibitor0.882
CYP450 3A4 inhibitorNon-inhibitor0.8714
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9691
Ames testNon AMES toxic0.7337
CarcinogenicityNon-carcinogens0.9557
BiodegradationNot ready biodegradable0.9746
Rat acute toxicity3.0638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9402
hERG inhibition (predictor II)Non-inhibitor0.9279
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-014i-6975000000-ecd49efa58246c903e23
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-d55749fa4d1f47ce2244
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kb-0095000000-83c78e9e15857145cc78
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-ad908ecfa38c7efce138
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0390000000-88d302b8770cb7121937
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03fu-0790000000-4af50b834ee854320001

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Isoquinolones and derivatives / Tetralins / Coumarans / Anisoles / Alkyl aryl ethers / Aralkylamines / Piperidines / Tertiary alcohols / Trialkylamines / 1,2-aminoalcohols
show 7 more
Substituents
Phenanthrene / Isoquinolone / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Cyclic alcohol / Tertiary alcohol
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound (CHEBI:7852)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
  3. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
  3. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT: Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007 Dec 5;132(3):289-300. Epub 2007 Apr 30. [PubMed:17467904]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
  2. DePriest AZ, Puet BL, Holt AC, Roberts A, Cone EJ: Metabolism and Disposition of Prescription Opioids: A Review. Forensic Sci Rev. 2015 Jul;27(2):115-45. [PubMed:26227254]
  3. Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Musshoff F: CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. PLoS One. 2013;8(3):e60239. doi: 10.1371/journal.pone.0060239. Epub 2013 Mar 28. [PubMed:23555934]
  4. Flockhart Table of Drug Interactions [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
  2. DePriest AZ, Puet BL, Holt AC, Roberts A, Cone EJ: Metabolism and Disposition of Prescription Opioids: A Review. Forensic Sci Rev. 2015 Jul;27(2):115-45. [PubMed:26227254]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
  2. DePriest AZ, Puet BL, Holt AC, Roberts A, Cone EJ: Metabolism and Disposition of Prescription Opioids: A Review. Forensic Sci Rev. 2015 Jul;27(2):115-45. [PubMed:26227254]
  3. Naito T, Takashina Y, Yamamoto K, Tashiro M, Ohnishi K, Kagawa Y, Kawakami J: CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol. 2011 Nov;51(11):1529-38. doi: 10.1177/0091270010388033. Epub 2011 Jan 5. [PubMed:21209234]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Leow KP, Wright AW, Cramond T, Smith MT: Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit. 1993 Oct;15(5):440-7. [PubMed:8249052]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Leow KP, Wright AW, Cramond T, Smith MT: Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit. 1993 Oct;15(5):440-7. [PubMed:8249052]

Drug created on June 13, 2005 07:24 / Updated on December 08, 2019 20:10